InMed Pharmaceuticals (INM) has released an update.
InMed Pharmaceuticals has appointed Dr. Barry Greenberg, a renowned expert in Alzheimer’s disease, to its Scientific Advisory Board. Dr. Greenberg’s extensive experience will be crucial as the company advances its INM-901 drug candidate towards human trials. This move highlights InMed’s commitment to developing effective therapies for Alzheimer’s disease.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
